Navigation Links
Oral VDA CYT997 - Phase I Clinical Trial Presentation at ASCO
Date:5/28/2009

MELBOURNE, Australia, May 28 /PRNewswire-FirstCall/ -- Cytopia Limited (ASX: CYT) announced that it will present preliminary data from its Phase I clinical trial of orally administered CYT997, at the Annual Meeting of the American Society of Clinical Oncologists (ASCO), in Orlando, Florida, USA.

Dr Alessandra Francesconi, one of the clinical investigators for the program, will be presenting the poster in the Developmental Therapeutics - Vascular Targeting poster session on Saturday 30th May from 8:00 AM to 12:00 PM (US EST), Level 2, West Hall C.

The poster entitled "Phase I evaluation of orally-administered CYT997, a novel cytotoxic vascular-disrupting agent, in patients with advanced cancer" details safety, tolerability and preliminary activity findings from this study, which concluded in February 2009. CYT997 is currently undergoing further clinical investigation in Phase II studies in relapsed glioblastoma multiforme and multiple myeloma.

Enquiries


    Dr. Gregg Smith                            Mr. Andrew Macdonald
    Director, Drug Development and Operations  Chief Executive Officer
    T: +61 3 9208 4234                         T: +61 3 9208 4232
    gregg.smith@cytopia.com.au                 andrew.macdonald@cytopia.com.au

About Cytopia

Cytopia Ltd is an Australian biotechnology company focused on the discovery and development of new drugs to treat
'/>"/>

SOURCE Cytopia Limited
Copyright©2009 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2

Related biology technology :

1. Cytopia Presentation on VDA CYT997 at AACR Conference
2. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
3. The Multiple Myeloma Research Consortium (MMRC) and Proteolix Initiate Phase 2 Clinical Trial Investigating Carfilzomib for the Treatment of Multiple Myeloma
4. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
5. ONCOSCIENCE AG, THE EUROPEAN PARTNER OF YM BIOSCIENCES, ANNOUNCES COMPLETION OF PATIENT ENROLLMENT IN PHASE III BRAIN CANCER TRIAL OF NIMOTUZUMAB
6. Evotec to Present Details of the Positive Phase II Study in Insomnia With EVT 201 at the Worldsleep07 Congress in Cairns/Australia
7. Phase III Trial Finds Pharmaxis Bronchitol Effective
8. YM BioSciences USA cleared by US FDA to initiate Phase II clinical trial of nimotuzumab in children with inoperable, recurrent brain cancer
9. YM BIOSCIENCES ANNOUNCES POSITIVE PRELIMINARY RESULTS FROM PHASE I/II LUNG CANCER TRIAL OF NIMOTUZUMAB COMBINED WITH RADIATION
10. Exelixis Reports Encouraging Interim Data From a Phase 2 Trial of XL647 as First-Line Therapy for Non-Small Cell Lung Cancer
11. Evotec Reports Details of the Positive Proof-of-Concept Phase II Study in Insomnia With EVT 201
Post Your Comments:
*Name:
*Comment:
*Email:
Breaking Biology News(10 mins):Study reveals H1N1 unexpected weakness 2Breakthrough in monitoring tropical deforestation announced in Copenhagen 2Uniform analyses for clean drinking water in Europe 2Blue Cross and Blue Shield of Florida Now Offers More Choices to Floridas Seniors 59742 1Blue Cross and Blue Shield of Florida Now Offers More Choices to Floridas Seniors 59742 2Blue Cross and Blue Shield of Florida Now Offers More Choices to Floridas Seniors 59742 3Encorium Group Inc Completes 241 6 Million Private Placement of Common Stock and Executes Warrant Exchange Agreement 3B Ends Discussions to Sell En 14524 1Encorium Group Inc Completes 241 6 Million Private Placement of Common Stock and Executes Warrant Exchange Agreement 3B Ends Discussions to Sell En 14524 2Encorium Group Inc Completes 241 6 Million Private Placement of Common Stock and Executes Warrant Exchange Agreement 3B Ends Discussions to Sell En 14524 3Encorium Group Inc Completes 241 6 Million Private Placement of Common Stock and Executes Warrant Exchange Agreement 3B Ends Discussions to Sell En 14524 4Encorium Group Inc Completes 241 6 Million Private Placement of Common Stock and Executes Warrant Exchange Agreement 3B Ends Discussions to Sell En 14524 5Antibiotic Resistant Infections Cost the U S Healthcare System in Excess of 2420 Billion Annually 5561 1Antibiotic Resistant Infections Cost the U S Healthcare System in Excess of 2420 Billion Annually 5561 2Antibiotic Resistant Infections Cost the U S Healthcare System in Excess of 2420 Billion Annually 5561 3Antibiotic Resistant Infections Cost the U S Healthcare System in Excess of 2420 Billion Annually 5561 4Antibiotic Resistant Infections Cost the U S Healthcare System in Excess of 2420 Billion Annually 5561 5Antibiotic Resistant Infections Cost the U S Healthcare System in Excess of 2420 Billion Annually 5561 6Antibiotic Resistant Infections Cost the U S Healthcare System in Excess of 2420 Billion Annually 5561 7